explore -WSS

explore

author：leisure time 2025-09-06 03:26:20 - browse：1

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： A $475,000 price tag for a new cancer drug: crazy or meh?

WSS

Montana youths win climate lawsuit against state for promoting fossil fuels

After Optum profits sink, UnitedHealth makes changes

Bird flu researchers hone in on Finland’s mink farms

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Timeline: How the deadly wildfires took over Maui day by day

explore

explore

knowledge

What does generative AI mean for health care? We asked experts

What we need to know about Arena Bioworks

Continuity nursing helped my family in our darkest PICU moments

Hospitals are dialing back on venture capital investing

Duchenne breakthrough therapy leaves behind pioneering families

Hospitals are dialing back on venture capital investing

Moonlake's readout produced a cash windfall. Risks remain

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Drug repurposing or repositioning? The language matters

Apple Vision Pro: A first look at health apps on the new VR headset

explore

Do digital therapeutics have a future in medicine?

Novo Nordisk touts Wegovy study, but still struggling with supply

The real point of Kenneth Smith’s execution by nitrogen gas

Surge in Apellis stock fueled by confidence in safety of its eye drug

Juul spent big to court Black leaders to promote its e

Novo Nordisk to expand supply of Wegovy for U.S. patients

focus

entertainment

focus

explore